Notably, therapies targeting glucagon‐like peptide‐1 (GLP‐1), a well‐established incretin hormone to enhance nutrient‐induced insulin release, have broadened treatment options and facilitated individualized management strategies for T2D [7, 8]. The gene discussed is INS; the disease is type 2 diabetes mellitus.